BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takagi H, Umemoto T; All-Literature Investigation of Cardiovascular Evidence Group. A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients. J Am Soc Hypertens 2014;8:578-92. [PMID: 25151319 DOI: 10.1016/j.jash.2014.05.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Naruse M, Koike Y, Kamei N, Sakamoto R, Yambe Y, Arimitsu M. Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open-label, randomized clinical trial. PLoS One 2019;14:e0214727. [PMID: 30943275 DOI: 10.1371/journal.pone.0214727] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Liu CH, Sung PS, Li YR, Huang WK, Lee TW, Huang CC, Lee TH, Chen TH, Wei YC. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study. PLoS Med 2021;18:e1003707. [PMID: 34280191 DOI: 10.1371/journal.pmed.1003707] [Reference Citation Analysis]
3 Kuwahara K, Honda T, Nakagawa T, Yamamoto S, Nanri A, Kurotani K, Hayashi T, Mizoue T. Strength training and risk of type 2 diabetes in a Japanese working population: A cohort study. J Diabetes Investig 2015;6:655-61. [PMID: 26543539 DOI: 10.1111/jdi.12347] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pushpakom S, Kolamunnage-dona R, Taylor C, Foster T, Spowart C, Garcia-finana M, Kemp GJ, Jaki T, Khoo S, Williamson P, Pirmohamed M. Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT. Efficacy Mech Eval 2019;6:1-168. [DOI: 10.3310/eme06060] [Reference Citation Analysis]
5 Liu CH, Lee TH, Lin YS, Sung PS, Wei YC, Li YR. Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study. Cardiovasc Diabetol 2020;19:2. [PMID: 31910836 DOI: 10.1186/s12933-019-0979-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
6 Wen J, Zeng M, Liu Z, Zhou H, Xu H, Huang M, Zhang W. The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics. J Pharmacol Sci 2019;139:37-41. [PMID: 30538075 DOI: 10.1016/j.jphs.2018.11.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Iyngkaran P, Liew D, McDonald P, Thomas MC, Reid C, Chew D, Hare DL. Phase 4 Studies in Heart Failure - What is Done and What is Needed? Curr Cardiol Rev. 2016;12:216-230. [PMID: 27280303 DOI: 10.2174/1573403x12666160606121458] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
8 Fan X, Copeland P, Nawras S, Harrington A, Freudenreich O, Goff DC, Henderson DC. Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial. Psychopharmacology (Berl) 2019;236:1949-57. [PMID: 30747254 DOI: 10.1007/s00213-019-5181-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Pushpakom S, Kolamunnage-Dona R, Taylor C, Foster T, Spowart C, García-Fiñana M, Kemp GJ, Jaki T, Khoo S, Williamson P, Pirmohamed M; TAILoR Study Group. TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. Clin Infect Dis 2020;70:2062-72. [PMID: 31425580 DOI: 10.1093/cid/ciz589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Cho KW, Cho DH. Telmisartan increases hepatic glucose production via protein kinase C ζ-dependent insulin receptor substrate-1 phosphorylation in HepG2 cells and mouse liver. Yeungnam Univ J Med 2019;36:26-35. [PMID: 31620609 DOI: 10.12701/yujm.2019.00059] [Reference Citation Analysis]